OptiBiotix is a life sciences company operating in one of the most progressive areas of biotechnological research – the modulation of the human microbiome. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix was founded in 2012 by Stephen O’Hara, founder and CEO, a visionary life science entrepreneur with a track record of building successful organisations (Acolyte Biomedica and Intelligent Biotech). OptiBiotix successfully listed on AIM in 2014 since when it has performed strongly.
Optibiotix initially engaged Sally Hope at PIR International to support the build out of the Board, hiring a Sales & Marketing Director and Commercial Director as part of the succession planning for the parent and subsidiary spin-outs. Subsequently, Sally was engaged to undertake the Search for a Non-Executive Chair, a role that would be fundamental in achieving the organisation’s aspirational growth strategy. Most recently, PIR International were engaged by Stephen O’Hara to undertake an extensive global CEO search for a new spin-out subsidiary business.
“I first engaged Sally and the team at PIR in 2017 for two Senior Commercial Director positions, and was impressed by their professionalism and ability to deliver a good range of suitable candidates. Since then PIR has become a trusted partner to OptiBiotix Health plc, they are great to work with; collaborative, transparent and through their Search process we have been able to successfully appoint a Chairman for our plc Board and a CEO based in the US for our newly created subsidiary ProBiotix Health. I look forward to continuing our successful partnership with PIR”
Stephen O’Hara, Chief Executive, OptiBiotix Health PLC